Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $8.6800 (-2.36%) ($8.4000 - $8.8200) on Thu. Mar. 7, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.67% (three month average) | RSI | 46 | Latest Price | $8.6800(-2.36%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -7% a day on average for past five trading days. | Weekly Trend | HTBX declines -5.5% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) GDX(11%) GLD(11%) IGOV(11%) GDXJ(10%) SHY(9%) | Factors Impacting HTBX price | HTBX will decline at least -2.835% in a week (0% probabilities). VCSH(-9%) XHB(-6%) UUP(-6%) JETS(-5%) CEMB(-5%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.835% (StdDev 5.67%) | Hourly BBV | 0 () | Intraday Trend | -1.6% | | | |
|
Resistance Level | $9.87 | 5 Day Moving Average | $9.02(-3.77%) | 10 Day Moving Average | $9.89(-12.23%) | 20 Day Moving Average | $9.87(-12.06%) | To recent high | -28.3% | To recent low | 26.5% | Market Cap | $955m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |